Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Galectin Therapeutics Inc

Ticker
GALT
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news highlights include widening losses reported in Q2 2026, plans for a Phase 3 MASH trial in Q3 2026, and FDA alignment on belapectin’s Phase III development path. The company has secured a $10 million credit line and continues to present clinical data supporting belapectin’s efficacy and safety.

Recent developments:
  • Galectin Therapeutics reported widening losses in Q2 2026 and announced plans to initiate a Phase 3 MASH trial in Q3 2026 [N1].
  • The company’s stock experienced gains following FDA alignment on belapectin’s Phase III development path for MASH cirrhosis [N4][N5].
  • Galectin secured a $10 million credit line to support ongoing development programs as of December 2025 [N6].
  • HC Wainwright & Co. maintained a buy recommendation on Galectin Therapeutics in December 2025 [N7].
  • The company continues to present positive clinical data from the NAVIGATE trial and other studies supporting belapectin’s potential benefits in MASH cirrhosis [N8].
Overview

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting galectin proteins, particularly galectin-3, which play a key role in fibrosis, immune regulation, and cancer. The company’s lead product candidate, belapectin, is a proprietary galectin-3 inhibitor derived from natural plant-based materials. Belapectin is primarily being developed for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. The company has conducted multiple clinical trials including Phase 1, Phase 2 (NASH-FX and NASH-CX), and a large global Phase 2b/3 NAVIGATE trial. The NAVIGATE trial completed enrollment in early 2023 and presented top-line results in late 2024, showing reductions in esophageal varices incidence and improvements in portal hypertension markers in certain patient populations. Belapectin has demonstrated a favorable safety profile with no drug-related serious adverse events. The company is also pursuing immuno-oncology indications and has ongoing FDA interactions guiding clinical development. As of September 30, 2026, Galectin reported cash and equivalents of $11.7 million and current liabilities exceeding current assets, indicating liquidity constraints. The company plans a Phase 3 MASH trial in Q3 2026 following FDA alignment.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies targeting galectin proteins, with a lead candidate belapectin focused on treating MASH cirrhosis and portal hypertension. The company has completed multiple clinical trials including a large Phase 2b/3 NAVIGATE trial, which showed reductions in esophageal varices incidence and portal hypertension markers. Belapectin's safety profile is favorable with no drug-related serious adverse events reported. As of September 30, 2026, the company reported $11.7 million in cash and equivalents and a current ratio of 0.28, indicating liquidity challenges. Recent news highlights include plans for a Phase 3 MASH trial in Q3 2026 and FDA alignment on belapectin's Phase III development path.

Scenarios for GALT

Bull case model:

Galectin Therapeutics has demonstrated clinical progress with belapectin in advanced MASH cirrhosis, showing reductions in esophageal varices and portal hypertension markers, supported by favorable safety data. FDA alignment on the Phase III development path and plans for a Phase 3 MASH trial in Q3 2026 indicate regulatory engagement. The company’s proprietary galectin-3 inhibitor platform targets a biologically validated pathway implicated in fibrosis and cancer, potentially addressing unmet medical needs. Additional development in immuno-oncology and ongoing clinical programs could expand the therapeutic scope. Strategic partnerships and financing could support advancement and commercialization efforts.

Bear case model:

Galectin Therapeutics faces significant liquidity constraints with current liabilities substantially exceeding current assets and a low current ratio as of September 30, 2026. The company has reported widening losses and depends on successful clinical trial outcomes and regulatory approvals to advance its lead candidate belapectin. Clinical trial results have shown mixed efficacy signals with some endpoints not reaching statistical significance in the intent-to-treat population. The company’s immuno-oncology programs are dependent on securing financing. The competitive landscape in fibrosis and oncology is challenging, and failure to demonstrate clear clinical benefit or secure partnerships could impede progress. Regulatory, clinical, and financial risks remain material.

Moat:

Galectin Therapeutics’ moat is based on its proprietary galectin-3 inhibitor technology platform, including patented complex carbohydrate molecules derived from natural plant-based materials. The company has established clinical data supporting belapectin’s potential efficacy and safety in treating fibrotic liver disease and portal hypertension in MASH cirrhosis patients. Its focus on galectin-3, a key mediator in fibrosis and immune pathways, addresses diseases with limited treatment options. The company’s clinical trial experience, FDA interactions, and intellectual property portfolio contribute to barriers for competitors. However, as a clinical-stage biopharmaceutical company, the moat is contingent on successful clinical development, regulatory approvals, and commercialization capabilities.

Risks overview
Risks summary
Liquidity constraints combined with clinical and regulatory uncertainties represent the primary risks to Galectin Therapeutics’ business progress.
Risks details:

• Liquidity Risk: As of September 30, 2026, the company’s current liabilities significantly exceed current assets, with a current ratio of 0.28 and cash ratio of 0.25, indicating potential challenges in meeting short-term obligations without additional financing.
• Clinical Development Risk: The success of belapectin depends on positive clinical trial outcomes. Some trials have shown mixed results, and failure to achieve statistically significant endpoints or safety concerns could delay or halt development.
• Regulatory Risk: Advancement of clinical programs relies on FDA feedback and approvals. Changes in regulatory requirements or unfavorable regulatory decisions could impact development timelines and commercialization.
• Financing Risk: The company’s immuno-oncology trials and other development programs depend on securing adequate financing. Inability to raise capital could delay or limit clinical progress.
• Competitive Risk: The fibrosis and oncology therapeutic areas are competitive with multiple companies developing treatments. Galectin’s products must demonstrate clear advantages to gain market acceptance.

FINAL FORECAST FOR GALT

Final take one line
Galectin Therapeutics is a clinical-stage biopharmaceutical company with detailed clinical programs for belapectin targeting MASH cirrhosis, facing liquidity challenges but progressing with FDA-aligned Phase III development.
Final take 12 to 24 month view

Business trends: Continued clinical development of belapectin with focus on MASH cirrhosis and portal hypertension, supported by FDA feedback and emerging clinical data.
Execution milestones: Initiation of Phase 3 MASH trial in Q3 2026, ongoing presentation of clinical trial results, and securing financing to support development.
Key risks: Liquidity constraints, clinical trial outcome uncertainties, regulatory approval challenges, and competitive pressures in fibrosis and oncology therapeutics.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company focused on drug research and development targeting galectin proteins, especially galectin-3, which are involved in fibrosis, immune function, and cancer.
  • The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor derived from natural plant-based materials, aimed primarily at treating metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension.
  • Belapectin has undergone multiple clinical trials including Phase 1, Phase 2 (NASH-FX and NASH-CX), and a large global Phase 2b/3 NAVIGATE trial for prevention of esophageal varices in MASH cirrhosis patients.
  • The NAVIGATE trial completed patient randomization in February 2023 and presented top-line results in December 2024, showing a reduction in varices incidence in the per-protocol population and significant reduction in the U.S. subgroup.
  • Belapectin demonstrated consistent effects on key biomarkers such as liver stiffness measurement (LSM) and ELF score, indicating potential reduction in fibrosis risk and liver function improvement.
  • Treatment with belapectin reduced clinically significant portal hypertension (CSPH) and lowered risk of hepatic decompensation, with safety profile comparable to placebo and no drug-related serious adverse events reported.
  • The company is pursuing additional clinical development in immuno-oncology, including a Phase 2 trial for head and neck squamous cell carcinoma in combination with a checkpoint inhibitor, pending financing.
  • Galectin Therapeutics secured a $10 million credit line and has ongoing FDA interactions guiding clinical development programs.
  • As of September 30, 2026, the company reported cash and equivalents of $11.7 million, current assets of $12.9 million, current liabilities of $46.4 million, resulting in a current ratio of 0.28 and cash ratio of 0.25, indicating liquidity constraints.
  • The company’s strategy includes advancing clinical programs efficiently and seeking strategic partners for advanced programs requiring significant resources.
  • Recent news highlights include plans for a Phase 3 MASH trial in Q3 2026, FDA alignment on belapectin’s Phase III path, and widening losses reported in Q2 2026.
  • The company has a history of presenting clinical data at scientific congresses and hosting key opinion leader events to support its development programs.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-08-19 | www.nasdaq.com | Galectin Loss Widens In Q2; Plans Phase 3 MASH Trial For Q3 2026 | https://www.nasdaq.com/articles/galectin-loss-widens-q2-plans-phase-3-mash-trial-q3-2026
  • N2 | 2026-07-14 | www.nasdaq.com | Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus | https://www.nasdaq.com/articles/top-biotech-gainers-qttb-sends-strong-signal-amwl-and-si-focus
  • N3 | 2026-06-25 | www.nasdaq.com | Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High | https://www.nasdaq.com/articles/top-biotech-gainers-plsm-inks-virtual-maternity-care-deal-iccm-turns-heads-sln-hits-new
  • N4 | 2026-06-24 | www.nasdaq.com | Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment | https://www.nasdaq.com/articles/top-biotech-gainers-bold-begins-anew-mnpr-nda-filing-track-galt-soars-fda-alignment
  • N5 | 2026-06-24 | www.nasdaq.com | GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH | https://www.nasdaq.com/articles/galt-jumps-11-fda-alignment-belapectin-phase-iii-path-mash
  • N6 | 2025-12-22 | www.nasdaq.com | Galectin Advances Belapectin Program With FDA Feedback And Secures $10 Million Credit Line | https://www.nasdaq.com/articles/galectin-advances-belapectin-program-fda-feedback-and-secures-10-million-credit-line
  • N7 | 2025-12-18 | www.nasdaq.com | HC Wainwright & Co. Maintains Galectin Therapeutics (GALT) Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-maintains-galectin-therapeutics-galt-buy-recommendation
  • N8 | 2025-09-12 | www.nasdaq.com | Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know | https://www.nasdaq.com/articles/galectin-therapeutics-inc-galt-748-one-week-what-you-should-know
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine